Actinium Pharmaceuticals ATNM 深 沪
交易中 09-10 11:03:44 美东时间
1.5999
0.000
-0.01%
华盛通- 最 高1.62
- 今 开1.585
- 成交量 2.81万股
- 最 低 1.56
- 昨 收 1.60
- 总市值 4991.03万
- 52周最高 2.41
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 1.0292
- 委 比 -45.50%
- 总股本 3119.59万
- 历史最高 450.00
- 量 比 0.89
- 振 幅 3.75%
- 历史最低 1.0292
- 每 手 1
- 风险率 2.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Advent Technologies and Stralis announce Pioneering Relationship to Advance Hydrogen Electric Flight
Advent Technologies Holdings, Inc. is supplying its proprietary membrane electrode assembly technology to Stralis Aircraft for their hydrogen electric Beechcraft Bonanza aircraft. Advent's HT-PEM technology reduces radiator size, weight, and drag, enabling efficient cooling. Stralis' hydrogen-electric propulsion system is significantly lighter, allowing flights 10 times farther than battery-electric alternatives at a lower cost. This system is ex...
08-18 12:30
ATN Announces Updated Start Time for Second Quarter 2025 Financial Results Conference Call on August 8, 2025
ATN International has announced a change to the start time of its Q2 2025 financial results conference call, which will now begin at 9:00 a.m. ET on Friday, August 8, 2025, one hour earlier than previously scheduled. All other details remain unchanged. The call will be webcast live and a replay will be available shortly after. The Company, headquartered in Beverly, Massachusetts, provides digital infrastructure and communications services to rura...
07-29 19:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Actinium Pharma Reports New Preclinical Data From Non-PSMA Targeting Radiotherapy Prostate Cancer Candidate ATNM-400, At SNMMI Annual Meeting
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination- ATNM-400 is
06-23 23:33
ATN Increases Dividend 15% as Part of Disciplined Capital Allocation Strategy
ATN International announced a 15% quarterly dividend increase to $0.275 per share, payable on July 7, 2025, to shareholders of record as of June 30, 2025. CEO Brad Martin highlighted the company's confidence in its financial strength and future cash flow, emphasizing investments in rural and remote markets and strategic initiatives for long-term shareholder value. ATN provides digital infrastructure and communications services in the U.S. and int...
06-20 14:30
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
05-13 08:50
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Actinium Pharma (AMEX:ATNM) with a Buy and maintains $4 price target.
05-13 00:15
H.C. Wainwright Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a ...
03-18 22:05
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
03-12 11:01
